Harmony Biosciences (HRMY) – Analysts’ Recent Ratings Changes

Harmony Biosciences (NASDAQ: HRMY) has recently received a number of price target changes and ratings updates:

• 10/19/2026 – Harmony Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $50.00 price target on the stock.
• 10/15/2026 – Harmony Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/15/2026 – Harmony Biosciences is now covered by LADENBURG THALM/SH SH. They set a “buy” rating and a $55.00 price target on the stock.
• 10/13/2026 – Harmony Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $55.00 price target on the stock.
• 10/12/2026 – Harmony Biosciences was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 10/12/2026 – Harmony Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $50.00 price target on the stock.
• 10/1/2026 – Harmony Biosciences had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $42.00 price target on the stock.
• 9/24/2026 – Harmony Biosciences had its “outperform” rating reaffirmed by Oppenheimer.
• 8/26/2026 – Harmony Biosciences is now covered by Wolfe Research. They set an “outperform” rating and a $60.00 price target on the stock.

Insider Activity

In related news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $43.05, for a total value of $1,543,428.60. Following the completion of the transaction, the insider owned 13,115 shares in the company, valued at $564,600.75. This trade represents a 73.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 72,406 shares of company stock valued at $3,108,520 over the last three months. Corporate insiders own 11.00% of the company’s stock.

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.